Aciex Therapeutics Enters Into Collaborative Research Agreement With Portola Pharmaceuticals, Inc. to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
Published: Feb 27, 2013
BOSTON--(BUSINESS WIRE)--Aciex Therapeutics, Inc. (Aciex) today announced that it has entered into a collaborative research agreement with Portola Pharmaceuticals, Inc. (Portola) that provides Aciex with exclusive rights to develop Portola’s small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for ophthalmic indications. The Portola library includes both compounds with extensive preclinical systemic data packages as well as earlier stage research compounds. The two companies will target development of drugs to treat topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions, for which there is a strong scientific rationale for Syk and JAK inhibition.